This website is for UK Healthcare Professionals only

This promotional material is intended for UK Healthcare Professionals experienced in the diagnosis and treatment of psoriasis and psoriatic arthritis. SKYRIZI® (risankizumab) and adalimumab prescribing information & adverse event reporting information can be found below.

Find out more about the efficacy of SKYRIZI

Explore the durability of response with SKYRIZI through clinical trials and long-term data in psoriasis and psoriatic arthritis. Start by selecting a study from the menu below.

SKYRIZI mode of action: Treat a cause, not an effect. Target a key driver of psoriatic inflammation.5-9

SKYRIZI binds with high specificity to the p19 subunit of IL-23, causing prolonged down-regulation of pathogenetic Th17 cells, leading to a reduction of proinflammatory cytokines.5-9

IL, interleukin; IFN-γ, interferon gamma; TGFβ, transforming growth factor beta; TH, T helper; TNFα, tumour necrosis factor alpha.

Featured content

The Retail Fitter 

A retail fitter, who has been struggling with severe plaque psoriasis and early psoriatic arthritis, has found relief and almost complete skin clearance with SKYRIZI. As a result, he no longer worries about missing time at work. 

How SKYRIZI works in 3 minutes

In under 3 minutes, Dr Laura Savage explains how SKYRIZI inhibits the IL-12/Th17 pathway using a split milk carton analogy.

More expert perspectives

View expert perspectives on SKYRIZI’s efficacy
data, dosing regimen and safety profile.

More expert perspectives

View expert perspectives on SKYRIZI’s efficacy data, dosing regimen and safety profile.

UK-RISN-240179. Date of preparation May 2024.

References

  1. Reich K, et al. Lancet 2019; 394: 576-586.
  2. Gordon KB, et al. Lancet 2018; 392: 650-661.
  3. Warren RB, et al. Risankizumab vs Secukinumab in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 3 Trial, Presented at AAD 2020.
  4. SKYRIZI: Summary of Product Characteristics.
  5. Gooderham MJ, et al. J Eur Acad Dermatol Venereol 2018; 32(7): 1111-1119.
  6. Kofoed K, et al. Acta Derm Venereol 2015; 95(2): 133-139.
  7. Gaffen SL, et al. Nat Rev Immunol 2014; 14(9): 585-600.
  8. Girolomoni G, et al. J Eur Acad Dermatol Venereol 2017; 31(1): 1616-1626.
  9. Lynde CW, et al. J Am Acad Dermatol 2014; 71(1): 141-150.

UK-RISN-240143. Date of preparation: May 2024.